The successful completion of the second proof-of-concept trial with OXPzeroTM Ibuprofen enhances the group’s data package on the product, enabling it to progress into partnering discussions. OXPzeroTM Ibuprofen has been optimised to provide immediate release and complete drug absorption as well as a taste masked benefit. The product has successfully demonstrated a reduction in the incidence and severity of GI damage. NSAIDs represent one of the most widely used drug classes in the world, but their use is associated with GI side effects. The group’s technology could potentially offer patients NSAIDs with an improved safety profile. We look forward to updates on commercial discussions in due course.
